156 related articles for article (PubMed ID: 27443611)
1. Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
Hoft DF; Lottenbach K; Goll JB; Hill H; Winokur PL; Patel SM; Brady RC; Chen WH; Edwards K; Creech CB; Frey SE; Blevins TP; Salomon R; Belshe RB
J Infect Dis; 2016 Oct; 214(7):1020-9. PubMed ID: 27443611
[TBL] [Abstract][Full Text] [Related]
2. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
3. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
4. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
6. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
7. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
8. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
9. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Sabarth N; Savidis-Dacho H; Schwendinger MG; Brühl P; Portsmouth D; Crowe BA; Kistner O; Barrett PN; Kreil TR; Howard MK
Vaccine; 2012 Aug; 30(37):5533-40. PubMed ID: 22749797
[TBL] [Abstract][Full Text] [Related]
10. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
Ledgerwood JE; Hu Z; Gordon IJ; Yamshchikov G; Enama ME; Plummer S; Bailer R; Pearce MB; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
Clin Vaccine Immunol; 2012 Nov; 19(11):1792-7. PubMed ID: 22956656
[TBL] [Abstract][Full Text] [Related]
11. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
12. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
Pantin-Jackwood MJ; Kapczynski DR; DeJesus E; Costa-Hurtado M; Dauphin G; Tripodi A; Dunn JR; Swayne DE
Avian Dis; 2016 Mar; 60(1):22-32. PubMed ID: 26953940
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus.
Niqueux E; Guionie O; Amelot M; Jestin V
Vaccine; 2013 Aug; 31(38):4121-8. PubMed ID: 23845804
[TBL] [Abstract][Full Text] [Related]
15. Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
Goy K; Von Bibra S; Lewis J; Laurie K; Barr I; Anderson D; Hellard M; Ffrench R
Influenza Other Respir Viruses; 2008 Jul; 2(4):115-25. PubMed ID: 19453462
[TBL] [Abstract][Full Text] [Related]
16. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
17. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.
Ledgerwood JE; Wei CJ; Hu Z; Gordon IJ; Enama ME; Hendel CS; McTamney PM; Pearce MB; Yassine HM; Boyington JC; Bailer R; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
Lancet Infect Dis; 2011 Dec; 11(12):916-24. PubMed ID: 21975270
[TBL] [Abstract][Full Text] [Related]
18. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.
Wang G; Zhou F; Buchy P; Zuo T; Hu H; Liu J; Song Y; Ding H; Tsai C; Chen Z; Zhang L; Deubel V; Zhou P
J Infect Dis; 2014 Mar; 209(5):676-85. PubMed ID: 23911711
[TBL] [Abstract][Full Text] [Related]
19. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
[TBL] [Abstract][Full Text] [Related]
20. Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.
Nayak JL; Richards KA; Yang H; Treanor JJ; Sant AJ
J Infect Dis; 2015 May; 211(9):1408-17. PubMed ID: 25378637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
